COBRA Notification

• All announcements
• By author, series, or subject in COBRA
• By subject area in COBRA
• RSS Feed

Most Popular Papers

• View the most frequently downloaded papers

Institutions: Join COBRA

• Add your collection to COBRA

About COBRA

• COBRA
• About bepress

Practical Model-Based Dose-Finding In Early Phase Clinical Trials: Optimizing tPA Dose For Treatment Of Ischemic Stroke In Children

• Harry T. Whelan, Division of Pediatric Neurology, Medical College of Wisconsin
• John D. Cook, M. D. Anderson Cancer Center
• Catherine M. Amlie-Lefond, Division of Pediatric Neurology, Medical College of Wisconsin
• Collin A. Hovinga, University of Tennessee Health Science Center, Dept. of Pharmacy and Pediatrics
• Anthony K. Chan, McMaster University Health Science Center
• Rebecca N. Ichord, Dept. of Neurology & Pediatrics Children's Hospital
• Gabrielle A. deVeber, Hospital for Sick Children, Division of Neurology
• Peter F. Thall, U.T.M.D. Anderson Cancer Center

Download the Paper Forward to a colleague

Abstract:

Background and Purpose: A safe and effective tissue plasminogen activator (tPA) dose for childhood stroke has not been established. This paper describes a Bayesian outcome-adaptive method for determining the best dose of an experimental agent, and explains how this method was used to design a dose-finding trial for tPA in childhood acute ischemic stroke (AIS).

Methods: The method assigns doses to successive cohorts of patients based on each dose’s desirability, quantified in terms of the trade-off between efficacy and toxicity. The trade-off function is constructed from several pairs of equally desirable (efficacy, toxicity) probabilities specified by the physicians planning the trial. Each cohort’s dose is chosen adaptively, based on dose-outcome data from the patients treated previously in the trial, to optimize the efficacy-toxicity trade-off. Application of the method to design the tPA trial is described, including a computer simulation study to establish the design’s properties. A hypothetical cohort-by-cohort example is given to illustrate how the method works during trial conduct.

Results and Conclusions: Because only a dose that is both safe and efficacious may be selected, and the method combines Phase I and Phase II by integrating efficacy and toxicity to choose doses, it avoids the more time-consuming and expensive conventional approach of conducting a Phase I trial based on toxicity alone followed by a Phase II trial based on efficacy alone. This is especially useful in settings with low accrual rates, such as trials of tPA for pediatric AIS.

Subject Area:

Clinical Trials

Suggested Citation:

Harry T. Whelan, John D. Cook, Catherine M. Amlie-Lefond, Collin A. Hovinga, Anthony K. Chan, Rebecca N. Ichord, Gabrielle A. deVeber, and Peter F. Thall, "Practical Model-Based Dose-Finding In Early Phase Clinical Trials: Optimizing tPA Dose For Treatment Of Ischemic Stroke In Children" (January 2008). UT MD Anderson Cancer Center Department of Biostatistics Working Paper Series. Working Paper 41.
http://www.bepress.com/mdandersonbiostat/paper41